Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Deficiency of Adenosine Deaminase 2 (DADA2) Presenting As Familial Hodgkin Lymphoma

Fahad Alabbas, Omar Alsharief, Isabelle Meyts, Fatma Albatniji, Michael Hershfield, Adnan Mansoor, MD PhD, Ghaleb Elyamany, MD PhD

Blood (2018) 132 (Supplement 1): 5373.

https://doi.org/10.1182/blood-2018-99-116431

Published: 2018

Journal Articles

Differential Gene Expression Using RNA Sequencing Between Elderly Acute Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival

Amy M Trottier, MD MSc, Adnan Mansoor, MD FRCPC, Carolyn J. Owen, MD MDes(UK), FRCPC, Ariz Akhter, PhD, Etienne Mahe, BSc, MD FRCPC, Michelle Geddes, MD FRCPC

Blood (2016) 128 (22): 1683.

https://doi.org/10.1182/blood.V128.22.1683.1683

Published: 2016

Journal Articles

Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series

Ryan J. Stubbins, MD BSc, Anthea C Peters, MD M.Sc., FRCPC, Mabilang Curtis, BSc, Carolyn Owen, MD, Adnan Mansoor, MD FRCPC, Raymond Lai, MD PhD, Jutta Preiksaitis, MD FRCPC

Blood (2015) 126 (23): 5008.

https://doi.org/10.1182/blood.V126.23.5008.5008

Published: 2015

Journal Articles

Gene-Expression for Prediction of Disease Progression Following Initial Management of Follicular Lymphoma

Etienne Mahe, BSc, MD FRCPC, Ariz Akhter, PhD, Danielle H. Oh, MB ChB, Fahad Farooq, BSc, Meer-Taher Shabani-Rad, MD FRCPC, Adnan Mansoor, MD FRCPC, Douglas A. Stewart, MD FRCPC

Blood (2015) 126 (23): 4804.

https://doi.org/10.1182/blood.V126.23.4804.4804

Published: 2015

Journal Articles

Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age

Cameron D. Griffiths, MD, Elena Liew, MD, Jennifer K. Grossman, MD, BSc, Douglas A. Stewart, MD, FRCP, Joanne Luider, Iwona Auer, Adnan Mansoor, MD, FRCPC, Michelle Geddes, MD

Blood (2012) 120 (21): 1424.

https://doi.org/10.1182/blood.V120.21.1424.1424

Published: 2012

Journal Articles

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Paola Neri, MD, PhD, Andrew R Belch, MD, Jordan Johnson, Kathy J Gratton, Li Ren, PhD, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar Bahlis, MD

Blood (2011) 118 (21): 987.

https://doi.org/10.1182/blood.V118.21.987.987

Published: 2011

Journal Articles

Immune Reconstitution After Antithymocyte Globulin (ATG)-Conditioned Hematopoietic Cell Transplantation (HCT)

Mark Bosch, MD, FRCPC, Manveer Dhadda, Mette Hoegh-Petersen, MD, Yiping Liu, Laura M Hagel, Peter Podgorny, Alejandra Ugarte-Torres, MD, Joanne Luider, Iwona Auer-Grzesiak, MD, FRCPC, Adnan Mansoor, MD, FRCPC, James A Russell, Jan Storek, MD, PhD

Blood (2011) 118 (21): 1981.

https://doi.org/10.1182/blood.V118.21.1981.1981

Published: 2011

Journal Articles

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Paola Neri, MD, PhD, Li Ren, PhD, Kathy Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar J Bahlis, MD

Blood (2010) 116 (21): 789.

https://doi.org/10.1182/blood.V116.21.789.789

Published: 2010

Journal Articles

High Herpesvirus-Specific T Cell Counts Are Associated with near-Zero Likelihood of Malignancy Relapse and a Low Likelihood of Infections Due to Any pathogen.

Mette Hoegh-Petersen, MD, Sarah Sy, Alejandra Ugarte-Torres, Tyler S Williamson, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Yiping Liu, Stephanie Liu, Kevin Fonseca, Faisal Khan, James A Russell, Jan Storek, MD, PhD

Blood (2010) 116 (21): 1285.

https://doi.org/10.1182/blood.V116.21.1285.1285

Published: 2010

Journal Articles

A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Nizar J Bahlis, MD, Carolyn J Owen, MD, FRCPC, Paola Neri, MD, PhD, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Kathy J Gratton, Peter Duggan, MD, FRCPC, Pietro Ravani, MD, PhD, Douglas A. Stewart, MD, FRCP

Blood (2010) 116 (21): 324.

https://doi.org/10.1182/blood.V116.21.324.324

Published: 2010

Journal Articles

Integrin β7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival.

Paola Neri, M.D., Li Ren, Ph.D., Kathy Gratton, Alex Klimowicz, Ph.D., Adnan Mansoor, MD, FRCPC, Douglas A. Stewart, MD, FRCPC, Nizar J Bahlis, MD

Blood (2009) 114 (22): 949.

https://doi.org/10.1182/blood.V114.22.949.949

Published: 2009

Journal Articles

miRNA Expression in Multiple Myeloma as Predictive Model of Response to Bortezomib.

Paola Neri, M.D., Kathy Gratton, Li Ren, Ph.D., Adnan Mansoor, MD, FRCPC, Peter Duggan, MD, Douglas A. Stewart, MD, FRCPC, Nizar J Bahlis, MD

Blood (2009) 114 (22): 4918.

https://doi.org/10.1182/blood.V114.22.4918.4918

Published: 2009

Journal Articles

An Automated and Quantitative Protein Expression-Based Classification System to Identify High Risk Multiple Myeloma Patients

Alex Klimowicz, Ph.D., Paola Neri, M.D., Adnan Mansoor, MD, FRCPC, Anthony Magliocco, M.D., Douglas A. Stewart, MD, FRCPC, Nizar J Bahlis, MD

Blood (2008) 112 (11): 735.

https://doi.org/10.1182/blood.V112.11.735.735

Published: 2008

Journal Articles

Reduced Adverse Effects and Improved Engraftment in the Pediatric Transplant Population upon Dilution of HPC, Cord Blood Products Prior to Infusion

Nicole L Prokopishyn, PhD, Victor A. Lewis, MD, Susan Berrigan, Debbie Kury, Adnan Mansoor, MD, FRCPC

Blood (2008) 112 (11): 4137.

https://doi.org/10.1182/blood.V112.11.4137.4137

Published: 2008

Journal Articles

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Nizar J Bahlis, MD, Kevin W. Song, Tommy Fu, Birgitte J Roland, MD, FCCMG, DABMG, Hong Chang, Doug Horsman, MD, PhD, Adnan Mansoor, MD, FRCPC, Christine Chen, MD, Esther Masih- Khan, Young Trieu, MSc, Helene Bruyere, MD, Douglas A. Stewart, MD, FRCPC, Donna E. Reece, MD

Blood (2008) 112 (11): 1731.

https://doi.org/10.1182/blood.V112.11.1731.1731

Published: 2008

Journal Articles

Validation of a Novel Tissue Array Based Classification of Multiple Myeloma (MM).

Nizar J Bahlis, MD, Alex Klimowicz, Ph.D., Paola Neri, M.D., Anthony Magliocco, M.D., Douglas A. Stewart, MD, FRCPC, Adnan Mansoor, MD, FRCPC

Blood (2008) 112 (11): 1671.

https://doi.org/10.1182/blood.V112.11.1671.1671

Published: 2008

Journal Articles

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

Nizar J. Bahlis, MD, Kevin Song, MD, Young Trieu, BS, MS, Birgitte Roland, MD, Esther Masih-Khan, PhD, Hong Chang, MD, Helene Bruyere, MD, Adnan Mansoor, MD, Douglas Horsman, MD, Michael Eliasziw, PhD, Douglas Stewart, MD, Donna Reece, MD

Blood (2007) 110 (11): 3597.

https://doi.org/10.1182/blood.V110.11.3597.3597

Published: 2007

Journal Articles

Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial.

Nizar J. Bahlis, MD, Adnan Mansoor, MD, Johannes C. Lategan, MD, Karen Valentine, MD, Tedd Thaell, MD, Walter Blahey, MD, Mary Lynn Savoie, MD, Kim Blaikie, RN, Leanne Kmet, PhD, Birgitte Roland, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3557.

https://doi.org/10.1182/blood.V108.11.3557.3557

Published: 2006

Journal Articles

Detection of FGFR3 by Immunohistochemistry in Multiple Myeloma Is Highly Predictive of t(4;14) by FISH and Is Associated with CD56 (NCAM1) Expression.

Nizar J. Bahlis, MD, Birgitte Roland, Toni Maggliocco, MD, PhD, Ivona Auer, MD, Douglas A. Stewart, MD, Adnan Mansoor, MD

Blood (2006) 108 (11): 5073.

https://doi.org/10.1182/blood.V108.11.5073.5073

Published: 2006

Journal Articles

Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Tranplantation — Evidence to Support the Existence of a Lymphoma Progenitor Cell.

Jason Hart, MD, A. Robert Turner, MD, Loree M. Larratt, MD, James A. Russell, MD, Bevin Franko, B.Sc., Christine Frantz, M.Sc, Teresa Paonessa, B.Sc, Adnan Mansoor, MD, M.Sc, Raymond Lai, MD, Ph.D

Blood (2006) 108 (11): 2415.

https://doi.org/10.1182/blood.V108.11.2415.2415

Published: 2006

NARROW

Deficiency of Adenosine Deaminase 2 (DADA2) Presenting As Familial Hodgkin Lymphoma

Differential Gene Expression Using RNA Sequencing Between Elderly Acute Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival

Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series

Gene-Expression for Prediction of Disease Progression Following Initial Management of Follicular Lymphoma

Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age

A miRNA Risk Score for the Prediction of Response to Lenalidomide in Multiple Myeloma (MM) Patients

Immune Reconstitution After Antithymocyte Globulin (ATG)-Conditioned Hematopoietic Cell Transplantation (HCT)

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

High Herpesvirus-Specific T Cell Counts Are Associated with near-Zero Likelihood of Malignancy Relapse and a Low Likelihood of Infections Due to Any pathogen.

A miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Integrin β7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival.

miRNA Expression in Multiple Myeloma as Predictive Model of Response to Bortezomib.

An Automated and Quantitative Protein Expression-Based Classification System to Identify High Risk Multiple Myeloma Patients

Reduced Adverse Effects and Improved Engraftment in the Pediatric Transplant Population upon Dilution of HPC, Cord Blood Products Prior to Infusion

The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Validation of a Novel Tissue Array Based Classification of Multiple Myeloma (MM).

Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in Multiple Myeloma: MM016 Trial.

Detection of FGFR3 by Immunohistochemistry in Multiple Myeloma Is Highly Predictive of t(4;14) by FISH and Is Associated with CD56 (NCAM1) Expression.

Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Tranplantation — Evidence to Support the Existence of a Lymphoma Progenitor Cell.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only